Thymulin

Thymulin is a thymic hormone whose activity depends on a nine-residue peptide binding zinc. This partnership gives the research an unusual measurement problem: peptide abundance, zinc availability and biological activity can move differently. Human studies have mostly examined the body's own thymulin during changes in zinc status or across age, while immune and endocrine interventions remain largely experimental. Understanding what each assay measured is the key to reading this literature.

Overview

The thymus provides a specialized environment for developing T cells. Its epithelial cells support that development through contact with neighboring cells and through secreted factors. Thymulin research examines one of those factors and its connections with immune and endocrine function. The original biochemical work described a circulating nonapeptide; subsequent zinc-binding experiments defined the active zinc-peptide complex. Bach et al., 1977, Dardenne et al., 1982.

The historical name serum thymic factor, or FTS, usually identifies the peptide component. FTS-Zn identifies the biologically active complex called thymulin. A result obtained with a metal-dependent activity assay needs that distinction: activity can fall even when peptide is present. FDA records the peptide component as nonathymulin and gives a formula that excludes zinc. The molecular fields therefore label the component separately from the active complex. FDA peptide identity.

Molecular profile

Peptide component: Serum thymic factor (FTS), a nonapeptide Source
Length: 9 amino-acid residues in the peptide component Source
Biologically active form: Zinc-bound serum thymic factor, FTS-Zn (thymulin) Source
Metal-dependent activity: Strongest activation at a 1:1 metal:peptide molar ratio in the original rosette bioassay Source
Peptide-component sequence: pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn-OH Source
Peptide-component formula: C33H54N12O15; excludes zinc and added counterions Source
Peptide-component UNII: 9H198D04WL (nonathymulin/serum thymic factor) Source

Forms and derivatives

FTS and FTS-Zn

FTS identifies the peptide component. Thymulin identifies its active zinc-bound form. Reports of activity depend on the assay and zinc state of the tested material.

metFTS expressed analogue

The developmental mouse studies used gene transfer to express methionine-FTS, a biologically active analogue. Continued expression changes the exposure pattern and the tested material. Those results belong to that animal intervention.

Uses and research areas

The human zinc-deficiency studies treated serum thymulin activity as a possible indicator of mild deficiency. They altered zinc status and measured endogenous hormone activity. Their relevance comes from asking whether the functional assay could detect a change missed by a routine plasma zinc measurement. Prasad et al., 1988.

Other investigations examine thymic-cell secretion, lymphocyte responses and communication with the pituitary gland. Human-origin epithelial cells in culture allow researchers to study secretion, while isolated rat pituitary tissue lets them measure individual hormone responses under controlled conditions. These systems address different portions of a biological relationship. The mouse gene-transfer studies add an intervention in animals with a profound thymic deficiency, helping investigate the role of the hormone during development. Saha et al., 1995, Hadley et al., 1997, Reggiani et al., 2009.

Mechanism of action

Zinc binding is part of the active hormone's identity. Dardenne and colleagues found that removing metal from natural or synthetic FTS abolished its activity in a cell-based rosette assay. Zinc restored activity, with the strongest activation at a one-to-one metal-to-peptide molar ratio. The experiment connected a chemical state with a measured biological response. Dardenne et al., 1982.

This creates two useful questions whenever a serum result is reported. How much peptide-related material was detected, and how much functional activity did it express? An assay that recognizes the peptide can answer the first question. An activity assay answers the second under its particular experimental conditions. A person's nutritional state, secretion and other physiological changes can influence the relationship between those measurements.

Researchers added zinc-bound thymulin to isolated anterior-pituitary tissue from rats and measured hormone release. Corticotrophin, also called ACTH, increased; this hormone signals the adrenal glands. Molecules that carry signals inside cells, called cyclic nucleotides, also increased. Growth-hormone release did not change in the same preparation, while prolactin release decreased. The result therefore concerns selective hormone responses in this isolated tissue rather than one uniform increase in pituitary activity. Hadley et al., 1997.

Together, the biochemical and tissue studies support a hormone with several context-dependent effects. They have not established a single receptor pathway that quantitatively predicts clinical benefit from administered thymulin in people.

Pharmacokinetics

Measurements of endogenous serum thymulin across age or zinc depletion describe physiology. They do not supply the absorption, distribution and elimination profile of an administered preparation. Gene-transfer studies pose a further distinction: their circulating activity includes ongoing production of an expressed analogue, so persistence in blood cannot be read as the elimination half-life of a peptide dose.

The acquired primary sources did not provide a verified route-specific human concentration–time series or numerical elimination estimate for administered thymulin. A curve is omitted, and the page keeps endogenous measurements within the studies that generated them.

Research findings

Mild zinc deficiency changed serum activity in small human groups

Prasad and colleagues studied two volunteers undergoing dietary zinc depletion, six mildly zinc-deficient adults with sickle-cell anemia and six other mildly deficient adults. Plasma zinc levels were normal. Serum thymulin activity decreased during deficiency and recovered with zinc supplementation; adding zinc to serum samples also restored measured activity. Prasad et al., 1988.

The intervention was zinc repletion, and the result supports the sensitivity of this functional hormone assay in those small groups. By comparing activity before and after repletion, the investigators examined how nutritional status influences an endogenous hormone. Thymulin activity was the physiological response measured during depletion and repletion.

Secretion and immune-cell responses differed by system

Saha and colleagues found that human thymic epithelial cells exposed to zinc released a factor that supported cultured lymphocyte responses. Removing material with antithymulin antibodies reduced that activity, supporting the authors' interpretation that the factor was zinc-thymulin. In a separate arm involving hydrocortisone-treated aged mice, administered zinc-thymulin mildly increased the responses of spleen-derived immune cells when those cells were later tested with immune-signaling proteins and plant-derived stimuli. The thymus-derived cells did not show that increase. Giving zinc itself increased responses in both tissues. The accessible abstract does not specify the physical assay used to quantify those mouse-cell responses. Saha et al., 1995.

The culture and animal arms locate different portions of the response. The secretion experiment helps identify a factor released by epithelial cells, while the animal arm examines how cells from separate immune tissues respond. The modest spleen response and unchanged thymocyte measurements make that tissue distinction part of the finding.

Human age measurements describe an endogenous pattern

Consolini and colleagues measured thymulin activity in 93 healthy individuals from birth through old age. The highest titres appeared among children aged five to ten, followed by a decline beginning in adolescence and lower values in adulthood. This was a cross-sectional description of people of different ages, with titres reported through an activity assay. Consolini et al., 2000.

The study supplies an age-related reference pattern for the assay. Whether an adult value can identify a useful treatment target requires a controlled intervention, a defined clinical outcome and an assessment of harms. The cross-sectional pattern provides the physiological starting point for that question.

Developmental mouse experiments used an expressed analogue

Reggiani and colleagues studied athymic nude mice, which lack normal thymic development. They used gene transfer so that the mice produced metFTS, an analogue of thymulin's peptide component. The intervention restored circulating thymulin activity and prevented a fall in gonadotropins, the pituitary hormones that regulate reproductive organs. It also changed the population of pituitary cells producing those hormones. The experiment investigated communication between a deficient thymus and endocrine tissues during development. Reggiani et al., 2009.

The material, developmental stage and deficiency model define the finding. Sustained production of an expressed analogue lets researchers investigate thymus–pituitary communication during development. A clinical study of native peptide replacement in aging adults would have a different baseline physiology and exposure.

Safety and tolerability

The human studies reviewed here do not characterize the safety of giving thymulin as a drug. A serum biomarker study can include people without exposing them to the compound whose activity is measured. Animal hormone changes also require clinical evaluation before benefits, endocrine disturbances or immune effects can be estimated in people.

Medsafe's 2025 classification submission described thymulin as a zinc-dependent metallopeptide and said its clinical risks remained unknown because therapeutic functions appeared to have been studied in animal models. This is a regulatory assessment within that submission, whose scope and date are stated explicitly. The official sources searched for this review did not identify an FDA-approved thymulin medicinal product. Medsafe submission.

FDA's current May 14, 2026 compounding-nomination document lists thymulin acetate in Category 3, substances nominated without adequate support. That record concerns a named bulk substance and does not characterize the efficacy or safety of an administered product. FDA nomination list.

What the research means

Thymulin provides a clear example of why a biological measurement needs an exact definition. An apparent decrease in hormone activity can reflect zinc availability as well as peptide production. The human zinc observations, epithelial-cell experiments and pituitary findings develop that explanation from different directions, while the age study describes an endogenous pattern in a healthy population.

Clinical interpretation requires an additional step: a controlled intervention using identified material, a defined population and outcomes that reflect how people function or feel. The selected literature leaves that step unresolved for therapeutic thymulin. Claims of immune restoration or hormone optimization therefore go beyond the patient outcomes measured in these sources.

FAQs

Why can thymulin activity fall when plasma zinc looks normal?

Plasma zinc and a hormone activity assay examine different aspects of physiology. The small human depletion study found reduced thymulin activity despite normal plasma zinc. The result helped investigate mild zinc deficiency; it does not establish a universal diagnostic threshold.

Were people given thymulin in the human zinc study?

The intervention altered zinc status. Investigators measured the body's own serum thymulin activity before and after repletion. A study that measures an endogenous compound answers a different question from a therapeutic trial administering it.

Does a lower adult thymulin titre mean replacement would improve aging?

The age study described differences across healthy individuals. A useful replacement claim would require a controlled intervention showing patient benefit and measuring harms. The observed age pattern does not supply that evidence.

Did every immune tissue respond in the mouse study?

In the aged-mouse experiment, investigators gave zinc-thymulin and later tested immune cells from two tissues. Cells taken from the spleen, called splenocytes, showed a modest response; developing T cells from the thymus, called thymocytes, did not show improvement in the measured responses. A separate zinc intervention produced a different pattern. These are distinct treatments and tissues, so the result cannot be summarized as a uniform improvement throughout the immune system.

What do the pituitary findings establish?

They show selective hormone responses in isolated rat tissue, including increased corticotrophin and unchanged growth-hormone release. They provide a way to investigate endocrine communication; therapeutic benefit in people needs a clinical outcome study.

Are gene-transfer results evidence for an administered thymulin preparation?

They describe ongoing production of an expressed analogue in thymus-deficient mice. The developmental model and exposure differ from administering a native peptide preparation. Their contribution is to understanding the role of the hormone in that model.

Is there a verified human pharmacokinetic curve?

The acquired primary sources did not supply a route-specific concentration series or numerical elimination estimate for administered thymulin. Endogenous titres and persistence after gene transfer cannot provide that curve.

Thymosin α1 is another thymic-associated peptide with a different structure and a substantial disease-specific clinical trial literature. Thymulin's zinc dependence makes its measurement problem especially instructive. Copper-binding GHK offers a separate example of how a metal and a peptide can form a distinct chemical identity, although its biological targets and evidence differ.

References

The retained sources cover zinc-dependent activity, human zinc repletion, isolated pituitary tissue and epithelial-cell/animal responses. Additional primary age and developmental studies provide context for interpreting endogenous measurements and expressed analogues.

Dardenne M, Pléau JM, Nabarra B, Lefrancier P, Derrien M, Choay J, Bach JF. Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proceedings of the National Academy of Sciences USA. 1982;79(17):5370–5373. DOI: 10.1073/pnas.79.17.5370.
Metal removal and repletion connect zinc binding with the hormone's activity in a rosette assay.
Prasad AS, Meftah S, Abdallah J, Kaplan J, Brewer GJ, Bach JF, Dardenne M. Serum thymulin in human zinc deficiency. Journal of Clinical Investigation. 1988;82(4):1202–1210. DOI: 10.1172/JCI113717.
Small human groups underwent zinc depletion or repletion while endogenous serum thymulin activity was measured.
Hadley AJ, Rantle CM, Buckingham JC. Thymulin stimulates corticotrophin release and cyclic nucleotide formation in the rat anterior pituitary gland. Neuroimmunomodulation. 1997;4(2):62–69. DOI: 10.1159/000097322.
Isolated rat pituitary tissue showed selective hormone responses, including increased corticotrophin and unchanged growth hormone.
Saha AR, Hadden EM, Hadden JW. Zinc induces thymulin secretion from human thymic epithelial cells in vitro and augments splenocyte and thymocyte responses in vivo. International Journal of Immunopharmacology. 1995;17(9):729–733. DOI: 10.1016/0192-0561(95)00061-6.
The original abstract separates secretion experiments, administered zinc-thymulin and a zinc intervention with differing splenocyte and thymocyte responses.
Bach JF, Dardenne M, Pléau JM, Rosa J. Biochemical characterisation of a serum thymic factor. Nature. 1977;266:55–57. DOI: 10.1038/266055a0.
The original characterization identifies a circulating thymus-dependent nonapeptide.
Consolini R, Legitimo A, Calleri A, Milani M. Distribution of age-related thymulin titres in normal subjects through the course of life. Clinical and Experimental Immunology. 2000;121(3):444–447. DOI: 10.1046/j.1365-2249.2000.01315.x.
The cross-sectional age study describes endogenous activity in healthy individuals from birth through old age.
Reggiani P, Martines E, Ferese C, Goya R, Cónsole G. Morphological restoration of gonadotrope population by thymulin gene therapy in nude mice. Histology and Histopathology. 2009;24(6):729–735. DOI: 10.14670/HH-24.729.
An expressed analogue restored circulating activity and altered endocrine outcomes in a developmental mouse model with thymic deficiency.
Medsafe. Proposed classification of peptide groups: submission to the 74th Medicines Classification Committee meeting. 2025; thymic peptide hormones section.
The dated official submission discusses the absence of established clinical therapeutic evidence and unknown clinical risks for thymulin.
U.S. Food and Drug Administration. Substance Registration System: Nonathymulin (serum thymic factor), UNII 9H198D04WL. Accessed October 13, 2026.
The official record identifies the peptide component and its sequence-related chemical name. Its elemental formula contains no zinc or added acetate.
U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
The dated current document lists thymulin acetate among Category 3 substances nominated without adequate support.

Glossary

Nonapeptide: A peptide containing nine amino-acid residues.
FTS: Serum thymic factor, the historical name for thymulin's peptide component.
Bioactivity: A biological response measured in a specified assay; it can differ from the amount of material detected chemically.
Titre: An assay result expressed through the dilution at which a specified response is detected.
Thymic epithelial cell: A cell in the thymus that helps support developing T cells and can secrete thymic factors.
Splenocyte: A cell obtained from the spleen; the term includes several immune-cell types.
Thymocyte: A developing T cell within the thymus.
Corticotrophin (ACTH): A pituitary hormone that stimulates the adrenal cortex.
Gonadotrope: A pituitary cell that releases the reproductive hormones LH and FSH.
Athymic: Lacking a normal thymus; nude mice provide one developmental model of this condition.
Pyroglutamate: A cyclized amino-acid residue at the start of the peptide sequence, written pGlu.